Mark Groper News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark groper. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Groper Today - Breaking & Trending Today

Ottawa-based life sciences startup lands US$11.5M in fresh equity to fund cutting-edge cancer drugs


An Ottawa-based startup working on treatments that use the body’s immune system to target cancer, COVID-19 and other diseases has landed millions of dollars in financing to ratchet up its research efforts.
Orion Biotechnology’s new series-A round worth US$11.5 million is being led by Keiretsu Forum, a global syndicate of angel investors headquartered in San Francisco. 
The new funding will help the firm expand its clinical trials of drug candidates produced by its proprietary platform that targets G-protein coupled receptors, or GPCRs, which play a key role in diseases such as cancer, HIV and acute respiratory distress syndrome (ARDS) associated with the virus that causes COVID-19. ....

United Kingdom , San Francisco , United States , John Jussup , Brian Mcgowan , Oliver Hartley , Keiretsu Forum Toronto , National Research Council Of Canada , Halogen Software , Keiretsu Forum , Winnipeg National Microbiology Laboratory , University Of Geneva , Mark Groper , Nobel Prize , Gregory Winter , Glaxo Wellcome , National Research Council , National Microbiology Laboratory , ஒன்றுபட்டது கிஂக்டம் , சான் பிரான்சிஸ்கோ , ஒன்றுபட்டது மாநிலங்களில் , ஈயந் மகோவெந் , ஆலிவர் ஹார்ட்லி , தேசிய ஆராய்ச்சி சபை ஆஃப் கனடா , ஆலசன் மென்பொருள் , வின்னிபெக் தேசிய நுண்ணுயிரியல் ஆய்வகம் ,

PHASE 1 TEST RESULTS FOR A NOVEL HIV PREVENTION GEL PRESENTED AT THE HIVR4P MEETING


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PHASE 1 TEST RESULTS FOR A NOVEL HIV PREVENTION GEL PRESENTED AT THE HIVR4P MEETING
Orion Biotechnology Canada Ltd.January 28, 2021 GMT
Ottawa, Canada, Jan. 28, 2021 (GLOBE NEWSWIRE) Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that they will be presenting the results of their Phase 1 study of OB-002H at the HIVR4P virtual meeting ( https://www.hivr4p.org/ ).
The OB-002H-101 Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of the OB-002H gel which is being developed for a HIV prevention indication. OB-002 is a CCR5 inhibitor with best-in-class in vitro potency and is being evaluated in other indications including oncology and COVID-19. The study was conducted at the BioVirtus Research Site, Józefów, ....

Brian Mcgowan , Ross Macleod Orion Biotechnology Canada Ltd , Biovirtus Research Site , Orion Biotechnology Canada Ltd , Biotechnology Canada Ltd , Chief Medical Officer , Orion Biotechnology , Mark Groper , Orion Biotechnology Canada , G Protein Coupled Receptors , Macleod Orion Biotechnology Canada , ஈயந் மகோவெந் , ரோஸ் மக்ல்ந்ட் ஒரையந் உயிரி தொழில்நுட்பவியல் கனடா லிமிடெட் , ஒரையந் உயிரி தொழில்நுட்பவியல் கனடா லிமிடெட் , உயிரி தொழில்நுட்பவியல் கனடா லிமிடெட் , தலைமை மருத்துவ அதிகாரி , ஒரையந் உயிரி தொழில்நுட்பவியல் , குறி க்ரோபேர் , ஒரையந் உயிரி தொழில்நுட்பவியல் கனடா , மக்ல்ந்ட் ஒரையந் உயிரி தொழில்நுட்பவியல் கனடா ,

ORION BIOTECHNOLOGY PROJECT AWARDED GRANT TO ADVANCE DRUG DISCOVERY


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ORION BIOTECHNOLOGY PROJECT AWARDED GRANT TO ADVANCE DRUG DISCOVERY
Orion Biotechnology Canada Ltd.January 14, 2021 GMT
Genève SWITZERLAND, Jan. 14, 2021 (GLOBE NEWSWIRE) Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that its drug discovery project was awarded funding of CHF 0.9M from Innosuisse, the Swiss Innovation Agency. The project will allow Orion, in collaboration with the University of Geneva, to further expand and optimize drug discovery capabilities using its novel platform. The proprietary platform driven by Dr. Oliver Hartley and his team at the University of Geneva delivers a novel approach to G Protein-Coupled Receptor (GPCR) targeting by precision-engineering natural peptide and protein analogs that bind to GPCR targets with both enhanced potency and tailored signaling a ....

Oliver Hartley , University Of Geneva , Orion Biotechnology Holding Sa , Anatole Klepatsky Orion Biotechnology Holding , Orion Biotechnology Holding , Swiss Innovation Agency , Swiss Innovation , Orion Biotechnology , Mark Groper , Biotechnology Holding , G Protein Coupled Receptors , Western Europe , Globe Newswire , ஆலிவர் ஹார்ட்லி , பல்கலைக்கழகம் ஆஃப் ஜிநீவ , ஒரையந் உயிரி தொழில்நுட்பவியல் வைத்திருத்தல் ச , ஒரையந் உயிரி தொழில்நுட்பவியல் வைத்திருத்தல் , சுவிஸ் கண்டுபிடிப்பு , ஒரையந் உயிரி தொழில்நுட்பவியல் , குறி க்ரோபேர் , உயிரி தொழில்நுட்பவியல் வைத்திருத்தல் , மேற்கு யூரோப் , உயிரி தொழில்நுட்பவியல் ,